/
MLTX
$16.50-$0.73 (-4.24%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.5B
85M shares
52-week range
$5.95 – $62.75
19% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$4.25
MoonLake Immunotherapeutics Class A Ordinary Shares
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
www.moonlaketx.com- Employees
- 130
- IPO / List date
- Apr 6, 2022
- HQ
- ZUG, V8
Held by traders on TradeandTell
No one on the platform currently holds MLTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 276,772 | $5.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MLTX yet.
